Royal Bank of Canada Increases Repligen (NASDAQ:RGEN) Price Target to $205.00

Repligen (NASDAQ:RGEN - Free Report) had its price objective increased by Royal Bank of Canada from $203.00 to $205.00 in a report released on Friday morning,Benzinga reports. They currently have an outperform rating on the biotechnology company's stock.

Several other equities research analysts have also recently weighed in on RGEN. Canaccord Genuity Group upped their price objective on shares of Repligen from $165.00 to $170.00 and gave the stock a "hold" rating in a research report on Friday. JPMorgan Chase & Co. boosted their target price on shares of Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a research report on Friday. Wolfe Research assumed coverage on shares of Repligen in a research report on Thursday, November 14th. They set a "peer perform" rating on the stock. Canaccord Genuity Group began coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a "hold" rating and a $165.00 price objective for the company. Finally, StockNews.com upgraded Repligen from a "sell" rating to a "hold" rating in a research note on Friday, January 3rd. One research analyst has rated the stock with a sell rating, five have issued a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $181.00.

Remove Ads

Repligen Stock Performance

Shares of RGEN traded down $3.27 during mid-day trading on Friday, hitting $161.47. 801,294 shares of the company's stock were exchanged, compared to its average volume of 624,058. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen has a 52 week low of $113.50 and a 52 week high of $203.13. The stock's 50-day simple moving average is $155.30 and its 200-day simple moving average is $148.57. The firm has a market cap of $9.05 billion, a price-to-earnings ratio of -316.61, a price-to-earnings-growth ratio of 4.54 and a beta of 0.99.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping analysts' consensus estimates of $0.41 by $0.03. The firm had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. On average, equities research analysts expect that Repligen will post 1.72 EPS for the current year.

Institutional Investors Weigh In On Repligen

Several hedge funds have recently modified their holdings of the company. CWM LLC raised its position in Repligen by 36.3% in the third quarter. CWM LLC now owns 428 shares of the biotechnology company's stock valued at $64,000 after purchasing an additional 114 shares during the last quarter. Creative Planning increased its stake in shares of Repligen by 32.6% in the third quarter. Creative Planning now owns 5,123 shares of the biotechnology company's stock valued at $762,000 after buying an additional 1,259 shares during the period. Blue Trust Inc. raised its holdings in Repligen by 113.4% in the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company's stock valued at $36,000 after buying an additional 127 shares during the last quarter. Raymond James & Associates raised its holdings in Repligen by 49.3% in the 3rd quarter. Raymond James & Associates now owns 82,277 shares of the biotechnology company's stock valued at $12,244,000 after buying an additional 27,158 shares during the last quarter. Finally, Greenleaf Trust acquired a new stake in Repligen during the 3rd quarter worth approximately $226,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.